Primary biliary cholangitis associated with Hashimoto's thyroiditis in adult patient
Keywords:
Colangitis Biliar Primaria, Tiroiditis Autoinmune, Poliendocrinopatías Autoinmunes.Abstract
The Primary biliary cholangitis is a rare disease, the author intends to describe the characteristics of primary biliary cholangitis, during the presentation of a clinical case in an adult patient, who comes to medical evaluation control with asthenia and adynamia of long evolution, with weight gain, history of hypothyroidism and autoimmune liver disease, when performing laboratory tests were diagnosed with primary biliary cholangitis and Hashimoto's thyroiditis for a final diagnosis of autoimmune polyglandular syndrome type IIIC. The need to investigate autoimmune causes in all patients with altered liver tests was evident.
Downloads
References
1. Maradiaga R. SÍNDROME POLIGLANDULAR AUTOINMUNE TIPO III C: REPORTE DE CASO. Rev Cient Cienc Méd. 2018[citado 11/12/2024];21(2): 56-9. Disponible en: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1817-74332018000200010&lng=es.
2. Pandit S, Samant H. Primary Biliary Cholangitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023[citado 12/12/2024]. Disponible en: https://www-ncbi-nlmnihgov.translate.goog/books/NBK459209/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc
3. Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021[citado 11/12/2024];113(3):170-84. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299325/
4. Pariente A. Colangitis (ex-cirrosis) biliar primaria. EMC-Tratado de Medicina. 2021[citado 11/12/2024];25(1):1-8. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1636541021446891
5. Rodríguez Lugo DA, Coronado Tovar JJ, Solano Villamarin GA, Otero RW. Primary Biliary Cholangitis. Part 2. State of the Art, Diagnosis, Associated Diseases, Treatment and Prognosis. Rev. gastroenterol. Perú. 2018[citado 12/12/2024]; 38(1):64-71.Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1022-51292018000100010&lng=es.
6. Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clinical Gastroenterology and Hepatology. 2023[citado 12/12/2024] ;21(8):2076-87. Disponible en: https://www.sciencedirect.com/science/article/pii/S1542356523001106
7. La Rosa HD, Jiménez J, Castellanos I, Velázquez M, Dorta Z, Román Y. Curso clínico y supervivencia de pacientes cubanos con colangitis biliar primaria. Instituto de Gastroenterología, 2003-2020. Rev haban cienc méd. 2022 [citado 12/12/2024];21(5). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2022000500005&lng=es.
8. Sendoya JD, Gutiérrez MC, Melgar CE. Riesgo cardiovascular en personas con colangitis biliar primaria, revisión de la literatura. Revista Med. 2024[citado 12/12 2024];32(1):63-74. Disponible en: http://www.scielo.org.co/scielo.php?pid=S012152562024000100063&script=sci_arttext
9. Jiménez F, La Rosa HD, Castellanos I, Velázquez M, Dorta Z, Román Y. Respuesta terapéutica al ácido ursodesoxicólico en pacientes cubanos con colangitis biliar primaria. Rev. cuba. investig. bioméd. 2023[citado 19/12/2024]; 42. Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S086403002023000100010&lng=es.
10. Díaz-González Á, Fontanillas N, Gil-Hernández E, Guilabert M, Londoño MC, Noguerol M, et al. Recomendaciones y criterios de calidad para mejorar el diagnóstico precoz de la colangitis biliar primaria. Gastroenterología y Hepatología. 2024[citado 19/12/2024]1;47(8):834-44. Disponible en: https://www.sciencedirect.com/science/article/pii/S0210570523004922
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 MEDISAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
